Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA.
Division of Research and Development, Jesse Brown Veterans Affairs Medical Center, Chicago, IL, USA.
J Neurosci Res. 2020 Apr;98(4):626-631. doi: 10.1002/jnr.24561. Epub 2019 Dec 3.
Acetyl salicylic acid, commonly known as aspirin, has been being widely used as an anti-inflammatory drug for almost 100 years. However, there was no receptor known for this popular drug. Recently, we have established that peroxisome proliferator-activated receptor alpha (PPARα) acts as a novel receptor of aspirin. Activation of PPARα by aspirin stimulated a series of downstream signaling pathways that could potentially ameliorate different Alzheimer's disease (AD)-related pathologies. In this mini-review, we have discussed how aspirin-PPARα interaction plays a pivotal role in the amelioration of AD pathology via the stimulation of neurotrophic factors, upregulation of plasticity-associated genes, and removal of plaque burden in hippocampal neurons.
乙酰水杨酸，俗称阿司匹林，作为一种抗炎药物，已经广泛应用近 100 年。然而，这种广受欢迎的药物却没有已知的受体。最近，我们已经确定过氧化物酶体增殖物激活受体α（PPARα）是阿司匹林的一种新型受体。阿司匹林激活 PPARα 会刺激一系列下游信号通路，这些通路可能有助于改善不同的阿尔茨海默病（AD）相关病理。在这篇简评中，我们讨论了阿司匹林-PPARα 相互作用如何通过刺激神经营养因子、上调与可塑性相关的基因以及清除海马神经元中的斑块负担，在改善 AD 病理方面发挥关键作用。
